Screener / SEC EDGAR /CIK 0001439222 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Agios Pharmaceuticals, Inc. AGIO

We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. 10-K, Item 1

Headquarters
Cambridge, MA
CEO
Brian Goff
Next results
around Feb 11, 2027
Compare with peers Embed

AGIO among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 48.0%, above 90% of 154 peers (their median 10.4%) REVENUE GROWTH 48.0% · above 90% Gross margin: 93.8%, above 97% of 107 peers (their median 63.4%) GROSS MARGIN 93.8% · above 97% Operating margin: -297.7%, above 4% of 138 peers (their median 10.2%) OPERATING MARGIN -297.7% · above 4% Net margin: -264.8%, above 4% of 153 peers (their median 6.8%) NET MARGIN -264.8% · above 4% FCF margin: -238.5%, above 5% of 144 peers (their median 10.1%) FCF MARGIN -238.5% · above 5%
AGIO Peer median Below the median

What changed

32 new risk paragraphs. 10-K filed Feb 12, 2026 against Feb 13, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Cash from operations −$373.0M vs net income −$412.8M (FY ending Dec 31, 2025)
  • Inventory +19.2% ($27.6M to $32.9M) vs revenue +48.0% ($36.5M to $54.0M), -28.8 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
7 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Table of Content s; Revenue Recognition - PYRUKYND® Product Revenue
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

32 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.

All 32 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    The development and commercialization of PYRUKYND® or AQVESME™ could be unsuccessful if:
  2. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Ongoing or unanticipated geopolitical events in countries where we may to have clinical trial sites could also negatively impact our ability to initiate, enroll and retain patients in, and conduct clinical trials.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with foreign exchange fluctuations, compliance with foreign manufacturing, customs, shipment and storage requirements, cultural differences in medical practice and clinical research, diminished protection of intellectual…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    For example, the USPI for PYRUKYND® includes a warning regarding the risk of potential hepatoceullar injury, and the USPI for AQVESME™ contains a boxed warning regarding the potential for hepatocellular injury. In addition, to mitigate the risk of hepatocellular injury, AQVESME™ is available only through the REMS program approved by the…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$14.2M$26.8M$36.5M$54.0M
Net income−$231.8M−$352.1M$673.7M−$412.8M
Operating cash flow−$309.5M−$296.1M−$389.8M−$373.0M
Free cash flow−$314.4M−$297.1M−$391.5M−$377.3M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$54.0M ▲ 48.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

6 filings in the last 30 days · SEC EDGAR

All filings
1 more

About the company

Agios Pharmaceuticals, Inc., Cambridge, MA · from the 10-K filed Feb 12, 2026

We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.

Headquarters
Cambridge, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AGIO/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.